Mr. Zine is the Executive Chairman of Roadmap Capital Inc. Previously, Mr. Zine was a Managing Director in Global Investment Banking at RBC Capital Markets, where he was responsible for providing strategic and financial advice to many of Canada’s largest corporations, entrepreneurs and private equity firms.
Mr. Zine has over 15 years of experience executing public or private equity and debt financings, as well as mergers & acquisitions for a wide range of Canadian companies in the consumer, retail, healthcare, transportation and industrials sectors. Notable transactions include the $7.5 billion acquisition of Viterra by Glencore, a $500 million Canadian Pacific equity offering, $750 million Teranet IPO, $900 million Tim Hortons IPO, $5.6 billion sale of Dofasco to Arcelor, and $300 million private debt offering by MDS Heathcare.
Prior to joining RBC Capital Markets, Mr. Zine worked at Royal Bank of Canada on a number of strategic projects, including the proposed merger between Royal Bank of Canada and Bank of Montreal.
Mr. Zine holds a M.Sc. in Financial Engineering from École des Hautes Études Commerciales, University of Montréal.
Mr. Cleland is co-founder, CEO, President and CIO of the Manager, and principal portfolio manager of the Roadmap Innovation Funds.
Mr. Cleland has a Bachelor of Arts (Honours, 1992/97) from Harvard University and earned his CFA designation in 2001.
After graduating from Harvard, Mr. Cleland worked in the Research Department at Midland Walwyn Capital (subsequently Merrill Lynch Canada) as Research Associate to the senior telecommunications services analyst. From March of 1998 to March of 2001, Mr. Cleland worked at Interward Capital Corporation, first as an analyst, and later as Associate Portfolio Manager, specializing in technology equities. He was founding portfolio manager at Northern Rivers Capital Management (“Northern Rivers”), where he managed the Northern Rivers Innovation Fund from May of 2001 until Northern Rivers was acquired by BluMont Capital in February of 2010. Together with Riadh Zine (bio below), he co-founded Roadmap Capital Inc. in the summer of 2013. Roadmap’s first fund, the Roadmap Innovation Fund I (RIF I), was closed to new money on June 30, 2014.
Former Senior Vice-President, Business Development at TransTech Pharma, Mr. Ireland has been involved in the pharmaceutical, specialty pharmaceutical and biotechnology industries for more than 25 years. Mr. Ireland managed transactions in 2006 and 2010 with Pfizer and Forest Laboratories, respectively, valued in excess of $2 billion in potential upfront fees and milestones, each with recurring double-digit royalties. Mr. Ireland brings international experience in business development, clinical development, research, sales, marketing and executive management to Roadmap Capital.
Mr. Ireland received his Bachelor of Science with Honours, Major in Biological Sciences from Brock University.
After completing an undergraduate degree in Electrical Engineering and a Masters in RF Engineering, Mr. Zine earned a Ph.D. in Electrical and Computer Engineering from the University of Calgary in 2006 with a focus on nanotechnology and MEMS engineering. He joined CMC Microsystems in 2007 as a Senior Engineer in Micro and Nanotechnology Fabrication. Mr. Zine was involved with projects related to GaN MMIC (Microwave Monolithic Integrated Circuits) process, MEMS and nanotechnology related products. In 2010, Mr. Zine moved to the Business Development Department to work as a Technology Advisor, Microsystems and Nanotechnology, where he worked on projects in Photonics, printed electronics and packaging.
Dr. Waksal was Co-founder and, at various times, the CSO, COO and CEO of ImClone Systems. ImClone was sold to Eli Lilly for $6.5 billion in 2008. Dr. Waksal is the author of 50 scientific publications as well as multiple patents and patent applications. He received his MD from Tufts University School of Medicine.
Mr. Glenn is former Chairman and CEO of SXC Health Solutions (SXC). Under Mr. Glenn’s leadership, the company grew from $5 million in revenues in 1998 to a run-rate of almost $2 billion by the time he retired in 2009. SXC is now Catamaran Corporation, with revenues expected to be over $14 billion in 2013, and a market capitalization of about $12 billion. Prior to joining SXC, Mr. Glenn enjoyed a 25-year career with Computer Data Systems, Inc., a software, systems integrator and outsourcing firm. Mr. Glenn received a full scholarship from the Union Carbide Corporation and earned his BSc (Mechanical Engineering) cum laude.
Dr. Holler was Founder and former CEO of ID Biomedical, which was sold to GlaxoSmithKline Inc. for a total consideration of $1.9 billion in 2005. Dr. Holler received his BSc and MD from University of British Columbia.
Mr. Gounden is CEO of Via Science, a software analytics firm using advanced mathematics and massive computing scale to solve complex problems. Prior to Via Science, Mr. Gounden was a first investor, advisor and co-founder of a number of MIT spinouts in areas such as bio-manufacturing, coatings and consumer products. His holdings include Manus Biosynthesis, LiquiGlide and Mirakel, two of which became profitable in their first year of operations. He has been featured in articles in the Wall Street Journal, Forbes and the Financial Times, and has been a frequent guest lecturer at Harvard Business School. Mr. Gounden graduated from Harvard University with a degree in Biochemistry and Molecular Biology.
Mr. Adams is CEO of VentriPoint. A scientist and a serial entrepreneur, Mr. Adams was President and CEO of the University of Toronto Innovations Foundation from 1999 until 2004. Mr. Adams’s prior experience includes research and executive positions with Boston Scientific, Pfizer and Corvita Canada. He has over 124 scientific publications and is a reviewer for major scientific journals, federal granting agencies and centres of excellence.
Dr. Baruch is a clinical cardiologist, practicing at Mount Sinai Hospital in Manhattan. He earned his MD from the Albert Einstein College of Medicine before doing his internal medicine residency and cardiology fellowship at Mount Sinai Medical Center in New York. His varied interests include atrial fibrillation, heart failure, cholesterol management and echocardiography. Over the past few years, he has published papers in the areas of atrial fibrillation, novel anticoagulants, heart failure and improving quality of care. He is a reviewer for a number of medical journals.
Ms. Escobar Bold worked in the Corporate Finance Branch of the Ontario Securities Commission for over six years. Prior to joining the Ontario Securities Commission, she practiced corporate and securities law at Wildeboer Dellelce LLP, with a particular emphasis on public and private finance transactions. Ms. Escobar Bold also focused on mergers & acquisitions, corporate governance and securities regulatory compliance matters.
Ms. Escobar Bold has been a member of the Law Society of Upper Canada for over ten years. She earned an Honours Bachelor of Arts from the University of Toronto and a Bachelor of Law from Osgoode Hall Law School.